MTHFD1L

Across TCGA pan-cancer cohorts, MTHFD1L mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MTHFD1L data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MTHFD1L mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTHFD1L expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where MTHFD1L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.420	0.892	<.001	40	view →
CCRCC	DFS	Quartile	II,III,IV	0.355	0.785	<.001	25	view →
LSCC	OS	Quartile	All	0.959	0.746	.011	13	view →
LUAD	OS	Median	All	0.714	1.000	<.001	11	view →
GBM	DFS	Median	All	0.835	0.529	.006	7	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MTHFD1L–PDAC (DFS)

Open the PDAC breakdown →